BHCM
AUTL

Boulder Hill Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Boulder Hill Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-57,191
Closed -$105K – 96
2023
Q1 		$105K Buy
+57,191
New +$112K 0.08% 118

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Boulder Hill Capital Management's AUTL Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of Autolus Therapeutics (AUTL) in Q2 2023, closing a stake of 57,191 shares — an estimated $105K sold.

Boulder Hill Capital Management first reported a position in AUTL in Q1 2023 and held it in 1 quarter. The position peaked at $105K in Q1 2023. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining Autolus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 57,191 Autolus Therapeutics shares in Q2 2023, an estimated $105K.
  • Boulder Hill Capital Management first reported a position in Autolus Therapeutics in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Autolus Therapeutics position peaked at $105K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.